Subcutaneous Adipose 11β-Hydroxysteroid Dehydrogenase Type 1 Activity and Messenger Ribonucleic Acid Levels Are Associated with Adiposity and Insulinemia in Pima Indians and Caucasians
The DOI matches its Crossref record; 41 of the 42 references it cites were found in a registry or an index.
Abstract
Metabolic effects of cortisol may be critically modulated by glucocorticoid metabolism in tissues. Specifically, active cortisol is regenerated from inactive cortisone by the enzyme 11 beta-hydroxysteroid dehydrogenase type 1 (11-HSD1) in adipose and liver. We examined activity and mRNA levels of 11-HSD1 and tissue cortisol and cortisone levels in sc adipose tissue biopsies from 12 Caucasian (7 males and 5 females) and 19 Pima Indian (10 males and 9 females) nondiabetic subjects aged 28 +/- 7.6 yr (mean +/- SD; range, 18-45). Adipose 11-HSD1 activity and mRNA levels were highly correlated (r = 0.51, P = 0.003). Adipose 11-HSD1 activity was positively related to measures of total (body mass index, percentage body fat) and central (waist circumference) adiposity (P < 0.05 for all) and fasting glucose (r = 0.43, P = 0.02), insulin (r = 0.60, P = 0.0005), and insulin resistance by the homeostasis model (r = 0.70, P < 0.0001) but did not differ between sexes or ethnic groups. Intra-adipose cortisol was positively associated with fasting insulin (r = 0.37, P = 0.04) but was not significantly correlated with 11-HSD1 mRNA or activity or with other metabolic variables. In this cross-sectional study, higher adipose 11-HSD1 activity is associated with features of the metabolic syndrome. Our data support the hypothesis that increased regeneration of cortisol in adipose tissue influences metabolic sequelae of human obesity.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This differential effect was largely related to the impact on β-cell function11,138.”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [138]
In the citing paper
“Whereas the onset of glucose lowering with the other two medications was slower, it was most sustained with rosiglitazone, with metformin demonstrating an intermediate pattern.”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [138]
In the citing paper
“Glibenclamide produced the greatest initial reduction in glycaemia, but was poorest in maintaining glucose control.”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [138]
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
A transgenic model of visceral obesity and the metabolic syndrome
Masuzaki, H., Paterson, J., Shinyama, H., Morton, N. M., Mullins, J. J., Seckl, J. R., & Flier, J. S. (2001) · Science · doi:10.1126/science.1066285 · Cited by 1,766
Rosmond, R., Dallman, M. F., & Björntorp, P. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.6.4843 · Cited by 871
Kotelevtsev, Y., Holmes, M. C., Burchell, A., Houston, P. M., Schmoll, D., Jamieson, P., Best, R., Brown, R., Edwards, C. R. W., Seckl, J. R., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.26.14924 · Cited by 858
The role of TNFα and TNF receptors in obesity and insulin resistance
Hotamisligil, G. S. (1999) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.1999.00490.x · Cited by 780 · cited 1×
“46 Fasting insulin (mU/liter) 45 [38–52] 38 [32–51] 0.”
Does central obesity reflect “Cushing's disease of the omentum”?
Bujalska, I. J., Kumar, S., & Stewart, P. M. (1997) · The Lancet · doi:10.1016/s0140-6736(96)11222-8 · Cited by 753
Seckl, J. R., & Walker, B. R. (2001) · Endocrinology · doi:10.1210/endo.142.4.8114 · Cited by 714
Self-citationTissue-Specific Dysregulation of Cortisol Metabolism in Human Obesity
Rask, E. (2001) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.3.1418 · Cited by 655
Self-citationPhillips, D. I. W., Barker, D. J. P., Fall, C. H. D., Seckl, J. R., Whorwood, C. B., Wood, P. J., & Walker, B. R. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.3.4634 · Cited by 596
Rosmond, R. (1998) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.83.6.1853 · Cited by 590
Research works printed but not linked: 1
- 1985, Diabetes mellitus
Cited by
Pathophysiology of human visceral obesity: an update
Tchernof, A., & Després, J.-P. (2013) · Physiological Reviews · doi:10.1152/physrev.00033.2011 · Cited by 2,583
“Activity and mRNA abundance of the enzyme in whole adipose tissue samples are increased in obese compared with lean women and men (104, 246, 306, 325, 371, 417, 587, 588).”
BackgroundPathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future
Kahn, S. E., Cooper, M. E., & Del Prato, S. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62154-6 · Cited by 1,743
11β-Hydroxysteroid dehydrogenase type 1: a tissue specific regulator of glucocorticoid response
Tomlinson, J. W., Walker, E. A., Bujalska, I. J., Draper, N., Lavery, G. G., Cooper, M. S., Hewison, M., & Stewart, P. M. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0031 · Cited by 969
“More recently, several clinical studies have examined 11 -HSD1 activity in sc abdominal adipose tissue from obese men and women including a population of obese Pima Indians (140, 202, 223).”
Mechanisms of obesity-induced hypertension
Kotsis, V., Stabouli, S., Papakatsika, S., Rizos, Z., & Parati, G. (2010) · Hypertension Research · doi:10.1038/hr.2010.9 · Cited by 627
The Pathogenetic Role of Cortisol in the Metabolic Syndrome: A Hypothesis
Anagnostis, P., Athyros, V. G., Tziomalos, K., Karagiannis, A., & Mikhailidis, D. P. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0370 · Cited by 613
“Interestingly, hepatic 11 -HSD1 activity was reduced in obese patients in some studies, suggesting a divergent regulation of 11 -HSD1 in different tissues (121, 125).”
BackgroundGlucocorticoids and cardiovascular disease
Walker, B. R. (2007) · European Journal of Endocrinology · doi:10.1530/eje-07-0455 · Cited by 529
Self-citationMisra, A., & Vikram, N. K. (2004) · Nutrition · doi:10.1016/j.nut.2004.01.020 · Cited by 392
Mechanisms of Glucocorticoid-Induced Insulin Resistance
Geer, E. B., Islam, J., & Buettner, C. (2014) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2013.10.005 · Cited by 392
11β-Hydroxysteroid dehydrogenase and the pre-receptor regulation of corticosteroid hormone action
Draper, N., & Stewart, P. M. (2005) · Journal of Endocrinology · doi:10.1677/joe.1.06019 · Cited by 375
“However, in vivo studies are less clear-cut with increased (Paulmyer-Lacroix et al. 2002, Lindsay et al. 2003), unchanged or even reduced 11 -HSD1 activity reported in obesity.”
BackgroundThe role of glucocorticoid action in the pathophysiology of the Metabolic Syndrome
Wang, M. (2005) · Nutrition & Metabolism · doi:10.1186/1743-7075-2-3 · Cited by 277
“The association of adipose 11β-HSD1 with BMI and other features of the Metabolic Syndrome was also found in populations of different ethnic backgrounds [137].”
The adipocyte as an active participant in energy balance and metabolism
Badman, M. K., & Flier, J. S. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.058 · Cited by 256
Adipocyte-Specific Glucocorticoid Inactivation Protects Against Diet-Induced Obesity
Kershaw, E. E., Morton, N. M., Dhillon, H., Ramage, L., Seckl, J. R., & Flier, J. S. (2005) · Diabetes · doi:10.2337/diabetes.54.4.1023 · Cited by 253
Glucocorticoids and 11beta-Hydroxysteroid Dehydrogenase in Adipose Tissue
Seckl, J. R. (2004) · Recent Progress in Hormone Research · doi:10.1210/rp.59.1.359 · Cited by 239
“glucocorticoid-dependent gene transcription have been inconclusive (Lindsay et al., 2003; Wake et al., 2003).”
InfluentialTataranni, P. A., & Ortega, E. (2005) · Diabetes · doi:10.2337/diabetes.54.4.917 · Cited by 238
Self-citationWake, D. J., Rask, E., Livingstone, D. E. W., Söderberg, S., Olsson, T., & Walker, B. R. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030286 · Cited by 231
Self-citationRegulation of 11β‐HSD Genes in Human Adipose Tissue: Influence of Central Obesity and Weight Loss
Engeli, S., Böhnke, J., Feldpausch, M., Gorzelniak, K., Heintze, U., Janke, J., Luft, F. C., & Sharma, A. M. (2004) · Obesity Research · doi:10.1038/oby.2004.3 · Cited by 211
Kaserer, T., Beck, K., Akram, M., Odermatt, A., & Schuster, D. (2015) · Molecules · doi:10.3390/molecules201219880 · Cited by 207
Kannisto, K., Pietiläinen, K. H., Ehrenborg, E., Rissanen, A., Kaprio, J., Hamsten, A., & Yki-Järvinen, H. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0153 · Cited by 205
Sandeep, T. C., Andrew, R., Homer, N. Z. M., Andrews, R. C., Smith, K., & Walker, B. R. (2005) · Diabetes · doi:10.2337/diabetes.54.3.872 · Cited by 205
Self-citation11β-hydroxysteroid dehydrogenase 1: translational and therapeutic aspects
Gathercole, L. L., Lavery, G. G., Morgan, S. A., Cooper, M. S., Sinclair, A. J., Tomlinson, J. W., & Stewart, P. M. (2013) · Endocrine Reviews · doi:10.1210/er.2012-1050 · Cited by 196
Boullu-Ciocca, S., Dutour, A., Guillaume, V., Achard, V., Oliver, C., & Grino, M. (2005) · Diabetes · doi:10.2337/diabetes.54.1.197 · Cited by 189
“It is known that obese patients have mild increased basal and stress-induced glucocorticoid synthesis (2,20) and enhanced GR mRNA and 11 -HSD-1 mRNA and activity in stromal and adipocyte compartments of AT (20–24), which correlate with several features of the metabolic syndrome such as central adiposity, fasting gluco…”
Background11β-hydroxysteroid dehydrogenases: changing glucocorticoid action
Seckl, J. R. (2004) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2004.09.001 · Cited by 185
Cooper, M. S., & Stewart, P. M. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1412 · Cited by 183
Cortisol—cause and cure for metabolic syndrome?
Walker, B. R. (2006) · Diabetic Medicine · doi:10.1111/j.1464-5491.2006.01998.x · Cited by 179
Self-citationWesterbacka, J., Yki-Järvinen, H., Vehkavaara, S., Häkkinen, A.-M., Andrew, R., Wake, D. J., Seckl, J. R., & Walker, B. R. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030596 · Cited by 178
Self-citationNon-alcoholic fatty liver disease in lean individuals
Albhaisi, S., Chowdhury, A., & Sanyal, A. J. (2019) · JHEP Reports · doi:10.1016/j.jhepr.2019.08.002 · Cited by 174
Morton, N. M. (2010) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2009.09.024 · Cited by 163
Inhibition of 11ß-hydroxysteroid dehydrogenase type 1 as a promising therapeutic target
Wamil, M., & Seckl, J. R. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2007.06.001 · Cited by 163
Feig, P. U., Shah, S., Hermanowski‐Vosatka, A., Plotkin, D., Springer, M. S., Donahue, S., Thach, C., Klein, E. J., Lai, E., & Kaufman, K. D. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01375.x · Cited by 161
“(%) White 26 (67) 26 (70) 29 (76) 26 (65) Black 3 (8) 5 (14) 3 (8) 3 (8) Hispanic 8 (20) 6 (16) 5 (13) 10 (25) Other 2 (5) 0 (0) 1 (3) 0 (0) Weight (kg)∗ 91.”
Glucocorticoids produce whole body insulin resistance with changes in cardiac metabolism
Qi, D., & Rodrigues, B. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00453.2006 · Cited by 162
“11 -HSD1 potentially contributes to obesity and insulin resistance in both rodents (103, 111) and humans (85, 98).”
Background(2007) · doi:10.1139/h06-102 · Cited by 160
Valsamakis, G., Anwar, A., Tomlinson, J. W., Shackleton, C. H. L., McTernan, P. G., Chetty, R., Wood, P. J., Banerjee, A. K., Holder, G., Barnett, A. H., et al. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032240 · Cited by 160
Yang, K., Guan, H., Arany, E., Hill, D. J., & Cao, X. (2008) · The FASEB Journal · doi:10.1096/fj.07-100735 · Cited by 159
Desbriere, R., Vuaroqueaux, V., Achard, V., Boullu‐Ciocca, S., Labuhn, M., Dutour, A., & Grino, M. (2006) · Obesity · doi:10.1038/oby.2006.92 · Cited by 156
Tissue Production of Cortisol by 11β‐Hydroxysteroid Dehydrogenase Type 1 and Metabolic Disease
WALKER, B. R., & ANDREW, R. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1367.012 · Cited by 150
Self-citationAndrogen metabolism in adipose tissue: Recent advances
Blouin, K., Veilleux, A., Luu-The, V., & Tchernof, A. (2008) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2008.10.035 · Cited by 164
11β‐HSD Type 1 Expression in Human Adipose Tissue: Impact of Gender, Obesity, and Fat Localization
Paulsen, S. K., Pedersen, S. B., Fisker, S., & Richelsen, B. (2007) · Obesity · doi:10.1038/oby.2007.233 · Cited by 136
11&Bgr;-Hydroxysteroid Dehydrogenase Type 1 and Obesity
Morton, N. M., & Seckl, J. R. (2008) · Frontiers of Hormone Research · doi:10.1159/000115363 · Cited by 134
Seckl, J. R., & Walker, B. R. (2004) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2004.09.007 · Cited by 154
Self-citationRapid Hepatic Metabolism of 7-Ketocholesterol by 11β-Hydroxysteroid Dehydrogenase Type 1
Schweizer, R. A. S., Zürcher, M., Balazs, Z., Dick, B., & Odermatt, A. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m313615200 · Cited by 130
Tomlinson, J. W., Finney, J., Gay, C., Hughes, B. A., Hughes, S. V., & Stewart, P. M. (2008) · Diabetes · doi:10.2337/db08-0495 · Cited by 131
“Within the sc depot, most studies, although not all have suggested increased expression with indices of obesity (25-29), but relative expression within the intra-abdominal depot remains controversial.”
BackgroundFeng, Y., Huang, S., Dou, W., Zhang, S., Chen, J., Shen, Y., Shen, J., & Leng, Y. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00826.x · Cited by 135
“…113–126 119 and is closely associated with the development of a cluster of metabolic abnormalities including insulin resistance, central obesity, hyperglycaemia and dyslipidaemia (Masuzaki et al., 2001; Lindsay et al., 2003; Lundgren et al., 2004; Valsamakis et al., 2004; Abdallah et al., 2005).”
BackgroundRole of glucocorticoids in the physiopathology of excessive fat deposition and insulin resistance
Asensio, C. S., Muzzin, P., & Rohner‐Jeanrenaud, F. (2004) · International Journal of Obesity · doi:10.1038/sj.ijo.0802856 · Cited by 152
Nair, S., Lee, Y. H., Lindsay, R. S., Walker, B. R., Tataranni, P. A., Bogardus, C., Baier, L. J., & Permana, P. A. (2004) · Diabetologia · doi:10.1007/s00125-004-1407-6 · Cited by 124
“Eight of these subjects overlapped with our previous study [9].”
BackgroundResultSelf-citationPurnell, J. Q., Kahn, S. E., Samuels, M. H., Brandon, D., Loriaux, D. L., & Brunzell, J. D. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.90769.2008 · Cited by 112
11β-Hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome
Wake, D. J., & Walker, B. R. (2004) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2003.11.015 · Cited by 124
Self-citationMorton, N. M., Ramage, L., & Seckl, J. R. (2004) · Endocrinology · doi:10.1210/en.2003-1674 · Cited by 111
Modulation of glucocorticoid metabolism by the growth hormone – IGF‐1 axis
Agha, A., & Monson, J. P. (2007) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2007.02763.x · Cited by 108
Anagnostis, P. G., Katsiki, N., Adamidou, F., Athyros, V. G., Karagiannis, A. I., Kita, M. D., & Mikhailidis, D. P. (2012) · Metabolism · doi:10.1016/j.metabol.2012.05.002 · Cited by 117
Omental 11β‐hydroxysteroid Dehydrogenase 1 Correlates with Fat Cell Size Independently of Obesity
Michailidou, Z., Jensen, M. D., Dumesic, D. A., Chapman, K. E., Seckl, J. R., Walker, B. R., & Morton, N. M. (2007) · Obesity · doi:10.1038/oby.2007.618 · Cited by 102
“Although in this study we did not measure 11 HSD1 activity levels because of limited sizes of biopsies, we expect, from previous studies (7,10), that activity and mRNA levels are correlated in abdominal subcutaneous adipose tissue biopsies.”
BackgroundResultSelf-citationHughes, K. A., Webster, S. P., & Walker, B. R. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.4.481 · Cited by 102
Self-citationCortisol correlates with metabolic disturbances in a population study of type 2 diabetic patients
Oltmanns, K. M., Dodt, B., Schultes, B., Raspe, H. H., Schweiger, U., Born, J., Fehm, H. L., & Peters, A. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02074 · Cited by 99
“This hypothesis is supported by findings demonstrating that 11beta-HSD1 elevation in adipose tissue of obese humans is associated with features of the metabolic syndrome (16, 17 ) although there was no difference in plasma cortisol (16).”
MethodThe Contribution of Visceral Adipose Tissue to Splanchnic Cortisol Production in Healthy Humans
Andrew, R., Westerbacka, J., Wahren, J., Yki-Järvinen, H., & Walker, B. R. (2005) · Diabetes · doi:10.2337/diabetes.54.5.1364 · Cited by 98
Self-citationDehydroepiandrosterone inhibits the amplification of glucocorticoid action in adipose tissue
Apostolova, G., Schweizer, R. A. S., Balazs, Z., Kostadinova, R. M., & Odermatt, A. (2005) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00442.2004 · Cited by 89
“expression of 11β-HSD1 found in subcutaneous adipose tissue from individuals with aquired obesity and by its positive correlation with the accumulation of subcutaneous and intra-abdominal fat, body mass index, percentage of body fat, waist circumference, as well as fasting glucose, insulin levels and insulin resistanc…”
BackgroundHirata, A., Maeda, N., Nakatsuji, H., Hiuge-Shimizu, A., Okada, T., Funahashi, T., & Shimomura, I. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.01.139 · Cited by 99
Dieudonné, M., Sammari, A., Santos, E. D., Leneveu, M.-C., Giudicelli, Y., & Pecquery, R. (2006) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2006.01.007 · Cited by 94
Boullu‐Ciocca, S., Achard, V., Tassistro, V., Dutour, A., & Grino, M. (2007) · Diabetes · doi:10.2337/db07-1316 · Cited by 100
“Increased concentrations of 11 -hydroxysteroid dehydrogenase type 1 (11 -HSD-1), the enzyme that catalyzes the local reactivation of circulating inert cortisone (11-dehydrocortisosterone in rodents) to cortisol (corticosterone) have been found in adipose tissue of obese patients (3–6) and are closely related to adipos…”
BackgroundTargeting the pre-receptor metabolism of cortisol as a novel therapy in obesity and diabetes
Gathercole, L., & Stewart, P. M. (2010) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2010.03.060 · Cited by 90
Sai, S., Esteves, C. L., Kelly, V., Michailidou, Z., Anderson, K., Coll, A. P., Nakagawa, Y., Ohzeki, T., Seckl, J. R., & Chapman, K. E. (2008) · Molecular Endocrinology · doi:10.1210/me.2007-0489 · Cited by 81
Drake, A. J., Livingstone, D. E. W., Andrew, R., Seckl, J. R., Morton, N. M., & Walker, B. R. (2005) · Endocrinology · doi:10.1210/en.2004-1063 · Cited by 77
Self-citationVeilleux, A., Rhéaume, C., Daris, M., Luu-The, V., & Tchernof, A. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2011 · Cited by 78
Comparative enzymology of 11β-hydroxysteroid dehydrogenase type 1 from six species
Arampatzis, S., Kadereit, B., Schuster, D., Balazs, Z., Schweizer, R. A. S., Frey, F. J., Langer, T., & Odermatt, A. (2005) · Journal of Molecular Endocrinology · doi:10.1677/jme.1.01736 · Cited by 76
“…of subcutaneous and intra-abdominal fat, body-mass index, percentage of body fat and waist circumference, as well as fasting glucose, insulin levels and insulin resistance (PaulmyerLacroix et al. 2002, Rask et al. 2002, Lindsay et al. 2003, Kannisto et al. 2004, Valsamakis et al. 2004).”
BackgroundAdipose tissue 11β-hydroxysteroid dehydrogenase type 1 expression in obesity and Cushing’s syndrome
Mariniello, B., Ronconi, V., Rilli, S., Bernante, P., Boscaro, M., Mantero, F., & Giacchetti, G. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02228 · Cited by 74
11β-hydroxysteroid dehydrogenase type 1 inhibitors: a review of recent patents
Boyle, C. D., & Kowalski, T. J. (2009) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543770902967658 · Cited by 74
“11β-HSD1 mRNA and enzyme activity are higher in adipose tissue of obese humans [18,19,21,30] and rodents [31].”
Disruption of glucocorticoid action by environmental chemicals: Potential mechanisms and relevance
Odermatt, A., Gumy, C., Atanasov, A. G., & Dzyakanchuk, A. A. (2006) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2006.09.010 · Cited by 88
Depot‐specific Regulation of the Conversion of Cortisone to Cortisol in Human Adipose Tissue
Lee, M., Fried, S. K., Mundt, S. S., Wang, Y., Sullivan, S., Stefanni, A., Daugherty, B. L., & Hermanowski‐Vosatka, A. (2008) · Obesity · doi:10.1038/oby.2008.207 · Cited by 73
“Previous studies on the relationship of obesity to adipose HSD1 reductase activity are conflicting (3,4,7,28), and our data suggest that this could be due to the homogenate assay used in prior studies or the denominator used for expression of the results (relative to tissue protein).”
BackgroundTomlinson, J., & Stewart, P. M. (2005) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0023 · Cited by 82
Evidence That the 11 β-Hydroxysteroid Dehydrogenase (11 β-HSD1) Is Regulated by Pentose Pathway Flux
McCormick, K. L., Wang, X., & Mick, G. J. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m506026200 · Cited by 72
Asensio, C. S., Cettour-Rose, P., Theander-Carrillo, C., Rohner‐Jeanrenaud, F., & Muzzin, P. (2004) · Endocrinology · doi:10.1210/en.2003-1679 · Cited by 80
Alberti, L., Girola, A., Gilardini, L., Conti, A., Cattaldo, S., Micheletto, G., & Invitti, C. (2007) · International Journal of Obesity · doi:10.1038/sj.ijo.0803677 · Cited by 77
Iniesta, R. R., & Al‐Dujaili, E. A. S. (2014) · BioMed Research International · doi:10.1155/2014/482704 · Cited by 87
Goedecke, J. H., Wake, D. J., Levitt, N. S., Lambert, E. V., Collins, M. R., Morton, N. M., Andrew, R., Seckl, J. R., & Walker, B. R. (2006) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2006.02552.x · Cited by 67
Self-citationHarmful effects of functional hypercortisolism: a working hypothesis
Tirabassi, G., Boscaro, M., & Arnaldi, G. (2013) · Endocrine · doi:10.1007/s12020-013-0112-y · Cited by 77
“Finally, levels and activity of 11bHSD1 in subcutaneous adipose tissue of overweight and obese subjects have been found to correlate both with obesity degree and IR [119, 143].”
Morton, N. M., Densmore, V., Wamil, M., Ramage, L., Nichol, K., Bünger, L., Seckl, J. R., & Kenyon, C. J. (2005) · Diabetes · doi:10.2337/diabetes.54.12.3371 · Cited by 66
“This view is supported by recent human studies showing that adipose 11 -HSD-1 correlates more strongly with insulin resistance than with adiposity per se (15,41).”
ResultVeilleux, A., Laberge, P. Y., Morency, J., Noël, S., Luu-The, V., & Tchernof, A. (2010) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2010.02.024 · Cited by 73
Insulin resistance induced by hydrocortisone is increased in patients with abdominal obesity
Darmon, P., Dadoun, F., Boullu-Ciocca, S., Grino, M., Alessi, M.-C., & Dutour, A. (2006) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00654.2005 · Cited by 59
Franks, P. W., Knowler, W. C., Nair, S., Koska, J., Lee, Y.-H., Lindsay, R. S., Walker, B. R., Looker, H. C., Permana, P. A., Tataranni, P. A., et al. (2004) · Hypertension · doi:10.1161/01.hyp.0000144294.28985.d5 · Cited by 59
Self-citationAnthrax lethal factor represses glucocorticoid and progesterone receptor activity
Webster, J. I., Tonelli, L. H., Moayeri, M., Simons, S. S., Leppla, S. H., & STERNBERG, E. M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1036973100 · Cited by 64
Insulin and Dexamethasone Dynamically Regulate Adipocyte 11β-Hydroxysteroid Dehydrogenase Type 1
Balachandran, A., Guan, H., Sellan, M. E., Uum, S. H. M. V., & Yang, K. (2008) · Endocrinology · doi:10.1210/en.2008-0088 · Cited by 68
Wake, D. J., Homer, N. Z. M., Andrew, R., & Walker, B. R. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0819 · Cited by 57
Self-citationWalker, B. R., & Seckl, J. R. (2003) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.7.6.771 · Cited by 57
Self-citationStomby, A., Andrew, R., Walker, B. R., & Olsson, T. (2014) · Diabetologia · doi:10.1007/s00125-014-3228-6 · Cited by 68
Self-citationModulation of glucocorticoid action and the treatment of type-2 diabetes
Tomlinson, J., & Stewart, P. M. (2007) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2007.07.003 · Cited by 59
Nakajima, S., Koh, V., Kua, L.-F., So, J., Davide, L., Lim, K. S., Petersen, S. H., Yong, W.-P., Shabbir, A., & Kono, K. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1600895 · Cited by 55
Paulsen, S. K., Pedersen, S. B., Jørgensen, J. O. L., Fisker, S., Christiansen, J. S., Flyvbjerg, A., & Richelsen, B. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1694 · Cited by 55
Walker, B. R. (2007) · Proceedings of the Nutrition Society · doi:10.1017/s002966510700523x · Cited by 54
“A number of groups (Rask et al. 2001, 2002; Paulmyer-Lacroix et al. 2002; Lindsay et al. 2003; Wake et al. 2003; Engeli et al. 2004; Kannisto et al. 2004) have now confirmed this observation in biopsies of subcutaneous adipose tissue from obese people.”
BackgroundSelf-citationSemmler, G., Wernly, S., Bachmayer, S., Wernly, B., Schwenoha, L., Huber-Schönauer, U., Stickel, F., Niederseer, D., Aigner, E., & Datz, C. (2021) · Clinical and Translational Gastroenterology · doi:10.14309/ctg.0000000000000326 · Cited by 53
“Although data on the associationwith increased IR—probably because of an altered steroid synthesis in increased visceral adipose tissue (31)—do exist (7,21,24,25), we specifically report a higher prevalence of IGT as reflected by a pathological OGTT.”
BackgroundIs There a Role for Bioactive Lipids in the Pathobiology of Diabetes Mellitus?
Das, U. N. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00182 · Cited by 57
“It was observed (234, 235) that 11β-HSD1 mRNA levels were higher in omental compared with subcutaneous preadipocytes.”
BackgroundSwarbrick, M. M., Zhou, H., & Seibel, M. J. (2021) · European Journal of Endocrinology · doi:10.1530/eje-21-0553 · Cited by 57
Gögebakan, Ö., Andres, J., Biedasek, K., Mai, K., Kühnen, P., Krude, H., Isken, F., Rudovich, N., Osterhoff, M. A., Kintscher, U., et al. (2012) · Diabetes · doi:10.2337/db10-0902 · Cited by 50
Biedasek, K., Andres, J., Mai, K., Adams, S., Spuler, S., Fielitz, J., & Spranger, J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016674 · Cited by 49
“Although obese individuals have normal cortisol plasma levels, intracellular glucocorticoid action in liver and adipose tissue were shown to be increased in some publications due to high 11beta-HSD1 expression levels and activity [1], [2], [3].”
BackgroundWoods, C. P., Corrigan, M., Gathercole, L., TAYLOR, A. E. R., Hughes, B. A., Gaoatswe, G., Manolopoulos, K. N., Hogan, A. E., O’Connell, J., Stewart, P. M., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-4120 · Cited by 55
11β-Hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of type 2 diabetes
Morgan, S., & Tomlinson, J. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2010.504713 · Cited by 51
“Within subcutaneous adipose tissue, 11b-HSD1 activity correlates with obesity and insulin resistance and may drive adipocyte differentiation [42-49].”
Gregory, S., Hill, D., Grey, B., Ketelbey, W., Miller, T., Muniz-Terrera, G., & Ritchie, C. W. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154246 · Cited by 45
TRAIL Modulates the Immune System and Protects against the Development of Diabetes
Bossi, F., Bernardi, S., Zauli, G., Secchiero, P., & Fabris, B. (2015) · Journal of Immunology Research · doi:10.1155/2015/680749 · Cited by 51
Makkonen, J., Westerbacka, J., Kolak, M., Sutinen, J., Cornér, A., Hamsten, A., Fisher, R. M., & Yki‐Järvinen, H. (2007) · International Journal of Obesity · doi:10.1038/sj.ijo.0803635 · Cited by 51
Peixoto, R. D. S., Turban, S., Battle, J. H., Chapman, K. E., Seckl, J. R., & Morton, N. M. (2008) · Endocrinology · doi:10.1210/en.2007-1028 · Cited by 58
Thieringer, R., & Hermanowski‐Vosatka, A. (2005) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.3.5.911 · Cited by 48
Blackett, P. R., & Sanghera, D. K. (2012) · Journal of clinical lipidology · doi:10.1016/j.jacl.2012.04.079 · Cited by 51
Sušić, D., & Varagić, J. (2016) · Medical Clinics of North America · doi:10.1016/j.mcna.2016.08.008 · Cited by 48
Metadata
- Authors
- Lindsay, R. S., Wake, D. J., Nair, S., Bunt, J., Livingstone, D. E. W., Permana, P. A., Tataranni, P. A., & Walker, B. R.
- Affiliations
- National Institutes of Health (US)
- Western General Hospital (GB)
- Corresponding author
- Tataranni, P. Antonio
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2003-06-01
- Volume
- 88
- Issue
- 6
- Pages
- 2738-2744
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W1978718098
- Cited by
- 225
- References
- 42
- Citations by year
- 2024: 2 · 2023: 1 · 2021: 6 · 2020: 1 · 2019: 5 · 2018: 3 · 2017: 5 · 2016: 4 · 2015: 9 · 2014: 10 · 2013: 9 · 2012: 10
- FWCI
- 16.14
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Physiology (medical) › Adipose Tissue and Metabolism
- Keywords
- 11β-hydroxysteroid dehydrogenase type 1, subcutaneous adipose tissue, cortisol, cortisone, adiposity, insulin levels, insulin resistance, metabolic syndrome, obesity, Pima Indians, ethnic differences, gene expression, fasting blood glucose
- MeSH terms
- Adipose Tissue, Adult, Cortisone, Female, Humans, Hydroxysteroid Dehydrogenases, Indians, North American, Insulin, Male, Obesity, RNA, Messenger, Subcutaneous Tissue, 11-beta-Hydroxysteroid Dehydrogenase Type 1, White People
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.